

SUBJECT: CONSENT AGENDA – UPDATED AS AT 20 JUNE 2022

Agenda item: 01e

Category: For Decision

## **Section A: Introduction**

Nine recommendations are being presented to the Board under the Consent Agenda for consideration. Detailed information on the items can be found in the relevant Committee papers in a dedicated folder on BoardEffect at:

https://gavi.boardeffect.co.uk/workrooms/6459/resources/190583

## Section B: Actions requested of the Board

The Gavi Alliance Board is requested to consider the following recommendations from the Gavi Alliance Governance Committee, Audit and Finance Committee and Programme and Policy Committee.

## **Decision One – Board Committee Chair Appointments**

The Gavi Alliance Governance Committee <u>recommends</u> to the Gavi Alliance Board that it:

<u>Appoint</u> Anne Schuchat as Chair of the Programme and Policy Committee effective 1 July 2022 and until 31 December 2023.

#### **Decision Two – Board and Committee Member Appointments**

The Gavi Alliance Governance Committee <u>recommends</u> to the Gavi Alliance Board that it:

- a) **Appoint Deena Schiff** as an Unaffiliated Board Member in the seat currently held by Helen Rees effective 1 July 2022 and until 30 June 2025;
- b) <u>Appoint</u> Aamer Ikram of Pakistan as Board Member representing the implementing country constituency in the seat currently held by Faisal Sultan of Pakistan, effective immediately and until 31 December 2023;
- c) <u>Appoint</u> Won Do-yeon as Alternate Board Member representing the Republic of Korea on the donor constituency anchored by the United States in the seat currently held by Takeshi Akahori of Japan, effective immediately and until 31 December 2023;



- d) **Appoint** the following to the Governance Committee effective immediately:
  - Takeshi Akahori (Board Member) until 31 December 2023
  - Aamer Ikram (Board Member) until 31 December 2023
- e) **Appoint** the following to the Audit and Finance Committee effective immediately:
  - Megan Cain (Alternate Board Member) until 31 December 2022

### **Decision Three – Appointment of Judge to Appeals Tribunal**

The Gavi Alliance Governance Committee <u>recommends</u> to the Gavi Alliance Board that it:

<u>Appoint</u> Joan Powers as a member of the Gavi Appeals Tribunal effective immediately for a term of five years.

# <u>Decision Four – Investment Committee Charter</u>

The Gavi Alliance Governance Committee <u>recommends</u> to the Gavi Alliance Board that it:

<u>Approve</u> the amendments to the Gavi Alliance Investment Committee Charter as set out in Annex A to Doc 01e.

# <u>Decision Five – COVAX Facility Governance</u>

The Gavi Alliance Governance Committee <u>recommends</u> to the Gavi Alliance Board that it:

**Extend** the term of the COVID-19 Vaccination Delivery Support Temporary Steering Committee to end December 2022.

### <u>Decision Six – UNICEF Procurement Fees</u>

The Gavi Alliance Audit and Finance Committee <u>recommends</u> to the Gavi Alliance Board that it:

- a) **Approve**, within the overall Partners' Engagement Framework,
  - i. A budget of US\$ 22 million for UNICEF Supply Division fees for the procurement of vaccines and related devices in 2023;
  - ii. A budget of US\$ 4.3 million for UNICEF Supply Division fees for the procurement of cold chain equipment for 2023;
  - iii. A budget of US\$ 1.35 million for UNICEF Supply Division fees for the procurement of diagnostics equipment in 2022; and



iv. A budget of US\$ 1.35 million for UNICEF Supply Division fees for the procurement of diagnostics equipment for 2023.

## b) Note that

- The proposed fees for 2023 exclude the potential impact of COVID-19 complexities, subject to completion of a review between UNICEF and Gavi; and
- ii. An update will be presented to the Audit and Finance Committee in October 2022.

## <u>Decision Seven - Funding Policy Review</u>

The Gavi Alliance Programme and Policy Committee <u>recommends</u> to the Gavi Alliance Board that it:

- a) <u>Grant</u> the Secretariat the authority to implement an approach to apply cofinancing flexibilities, as described in Annex B to Doc 01e in countries facing severe fiscal distress and/or countries facing a humanitarian crisis, noting that this shift was approved by the Board in December 2019 for incorporation into Gavi's new funding policies; and
- b) **Note** the Framework for Gavi Funding to Countries.

## **Decision Eight – Innovation Approach for Gavi 5.0**

The Gavi Alliance Programme and Policy Committee <u>recommends</u> to the Gavi Alliance Board that it:

- a) **Approve** the overall innovation approach for Gavi 5.0 as laid out in Annex C to Doc 01e; and
- b) **Approve** US\$ 50 million in additional funding for Health System Strengthening (HSS) in Gavi 5.0 for countries interested in scaling proven innovations to be allocated, in accordance with the Programme Funding Policy, above HSS country ceilings on an exceptional basis.

#### **Decision Nine – Malaria Vaccine Implementation Programme**

The Gavi Alliance Programme and Policy Committee <u>recommends</u> to the Gavi Alliance Board that it:

- a) <u>Approve</u> an increase in the amount of funds for Phase 2 MVIP activities from US\$ 11.6 million to US\$ 12.25 million by allocating the Phase 1 underspend (US\$ 650,000) to be applied towards the previously approved Phase 2 activities; and
- b) **Note** that any underspend from the Phase 2 activities are to be returned to Gavi in accordance with the terms of the grant agreement.